A Phase I Study of Dalteparin, a Low Molecular Weight Heparin (LMWH), in Combination With Sunitinib (SU11248), an Oral, Selective Multitargeted Tyrosine Kinase Inhibitor, as First Line Treatment, in Patients With Metastatic Renal Cell Carcinoma
Latest Information Update: 10 Aug 2022
At a glance
- Drugs Dalteparin sodium (Primary) ; Sunitinib (Primary)
- Indications Renal cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 25 Apr 2017 Status changed from active, no longer recruiting to completed.
- 13 Jul 2016 This trial was completed in Netherlands (end date: 2015-10-14) according to European Clinical Trials Database record.
- 03 Jun 2014 Interim results (n=19) presented at the 50th Annual Meeting of the American Society of Clinical Oncology.